The results of our study suggest that patients with metaboliccomorbidities, particularly diabetes, subtle LV dysfunction and evident diastolicdysfunction might benefit more from treatment targeting MPO while patients withpredominant arterial stiffness (mostly females) and hyper contractile LV might beless responsive. The gene discussed is MPO; the disease is diabetes mellitus.